Patents by Inventor Birgit Linhart
Birgit Linhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160257722Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: ApplicationFiled: December 17, 2015Publication date: September 8, 2016Applicant: BIOMAY AGInventors: Rudolf VALENTA, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Gronlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Patent number: 9296828Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: GrantFiled: June 11, 2007Date of Patent: March 29, 2016Assignee: BIOMAY AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Patent number: 9103835Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.Type: GrantFiled: September 9, 2010Date of Patent: August 11, 2015Assignee: BIOMAY AGInventors: Rudolf Valenta, Birgit Linhart, Margarete Focke-Tejkl, Angela Neubauer, Peter Valent, Katharina Blatt
-
Patent number: 8709435Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: GrantFiled: July 8, 2011Date of Patent: April 29, 2014Assignee: Biomay AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Margarete Focke-Tejkl, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Birgit Linhart, Dietrich Kraft
-
Publication number: 20120207788Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.Type: ApplicationFiled: September 9, 2010Publication date: August 16, 2012Applicant: BIOMAY AGInventors: Rudolf Valenta, Birgit Linhart, Margarete Focke-Tejkl, Angela Neubauer, Peter Valent, Katharina Blatt
-
Publication number: 20120171238Abstract: The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.Type: ApplicationFiled: September 10, 2010Publication date: July 5, 2012Applicant: BIOMAY AGInventors: Rudolf Valenta, Kavita Reginald, Kerstin Westritschnig, Birgit Linhart, Angelika Stöcklinger, Josef Thalhamer, Alexander M. Hirschi, Thomas Werfel, Elli Greisenegger, Tamara Kopp
-
Publication number: 20120009210Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Applicant: BIOMAY AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Margarete Focke-Tejkl, Birgit Linhart, Dietrich Kraft
-
Publication number: 20110150920Abstract: Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.Type: ApplicationFiled: November 26, 2010Publication date: June 23, 2011Applicant: Biomay AGInventors: Birgit Linhart, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7862828Abstract: Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.Type: GrantFiled: December 27, 2001Date of Patent: January 4, 2011Assignee: Biomay AGInventors: Birgit Linhart, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20100203640Abstract: The present invention relates to a method for inducing specific long-lasting robust immunological tolerance towards at least one polypeptide derived from at least one allergen by transplanting a hematopoietic (stem) cell which is produced to display the said at least one polypeptide derived from at least one allergen.Type: ApplicationFiled: June 5, 2008Publication date: August 12, 2010Applicant: BIOMAY AGInventors: Thomas Wekerle, Rudolf Valenta, Ulrike Baranyi, Birgit Linhart, Nina Pilat, Jessamyn Bagley, John Iacomini, Martina Gattringer
-
Publication number: 20090324501Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: ApplicationFiled: June 11, 2007Publication date: December 31, 2009Applicant: Biomay AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renat Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Publication number: 20090148466Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: ApplicationFiled: January 7, 2009Publication date: June 11, 2009Applicant: BIOMAY AGInventors: Nadine MOTHES, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20090098167Abstract: Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen.Type: ApplicationFiled: May 3, 2007Publication date: April 16, 2009Applicants: BIOMAY AG, ALLERGOPHARMA JOACHIM GANZER KGInventors: Tanja Ball, Birgit Linhart, Peter Valent, Angelika Stocklinger, Christian Lupinek, Josef Thalhamer, Rudolf Valenta
-
Patent number: 7491396Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: GrantFiled: December 18, 2003Date of Patent: February 17, 2009Assignee: Biomay AGInventors: Nadine Mothes, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20060263391Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: ApplicationFiled: December 18, 2003Publication date: November 23, 2006Inventors: Nadine Mothes, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20020173625Abstract: Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.Type: ApplicationFiled: December 27, 2001Publication date: November 21, 2002Inventors: Birgit Linhart, Dietrich Kraft, Rudolf Valenta